RPRX — Royalty Pharma Plc · P/E 15, rev $1.30B

Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.

Latest reported RPRX revenue for 2026-06-30 was $1.30B. Net income was $312.6M. RPRX currently screens at market cap $20.45B and trailing P/E 14.8.

Use this RPRX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RPRX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RPRX SEC filings page. Lician reads the product cache first so this HTML stays unique to Royalty Pharma Plc even when a live quote feed is slow.

Royalty Pharma Plc latest statements (FY2025)

Latest cached year on this hub. Full RPRX income, balance, and cash tables.

  • Revenue$2.38B
  • Net Income$770.9M
  • Total Assets$19.62B
  • Total Debt$0
  • Free Cash Flow$0

RPRX recent filings